<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02152670</url>
  </required_header>
  <id_info>
    <org_study_id>1403013567</org_study_id>
    <nct_id>NCT02152670</nct_id>
  </id_info>
  <brief_title>Understanding Dopamine Mechanisms in Cocaine Addiction Using AMPT and Methylphenidate With [11C]RAC/[11C]PHNO PET</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Studies using positron emission tomography (PET) have been used with great success in&#xD;
      demonstrating specific abnormalities in several facets of dopaminergic system function in&#xD;
      human populations (Narendran and Martinez 2009). Among the first, most consistent, and&#xD;
      broadly replicated of such findings in drug- (including cocaine) dependent individuals has&#xD;
      been the reduction in subcortical (striatal) D2/3 receptors as imaged, most commonly, by the&#xD;
      reversible, non-selective, D2/3 receptor antagonist radiotracer, [11C]raclopride. Certain&#xD;
      dissociations on D2/3 availability by radioligand ([11C]raclopride vs. [11C]PHNO) and by&#xD;
      brain region (striatum vs. SN; terminal vs. somatodendritic, respectively) are poorly&#xD;
      understood in relationship to prior antagonist tracer results. In the current study the&#xD;
      investigators will use pharmacological interventions (AMPT and methylphenidate) with both&#xD;
      antagonist and agonist radiotracers to experimentally reconcile these discordant findings and&#xD;
      clarify potential mechanistic inter-relationships.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study drug became unaffordable for the purposes of the research.&#xD;
  </why_stopped>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">June 9, 2014</completion_date>
  <primary_completion_date type="Actual">June 9, 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BPND</measure>
    <time_frame>2 weeks</time_frame>
    <description>BPND is a measure of dopamine receptor availability</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Cocaine Dependence</condition>
  <arm_group>
    <arm_group_label>Baseline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 2 baseline PET scans with the radioligands (11C)(+)PHNO and (11C)(+)raclopride</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dopamine Release</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 1 PET scan following a PO dose of 60mg of methylphenidate to facilitate dopamine release with the radioligand (11C)(+)PHNO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Endogenous Dopamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 2 PET scans following 48 hours of dopamine depletion via AMPT with the radioligands (11C)(+)PHNO and (11C)(+)raclopride</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylphenidate</intervention_name>
    <arm_group_label>Dopamine Release</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alpha Methyl Para Tyrosine (AMPT)</intervention_name>
    <arm_group_label>Endogenous Dopamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>[11C]PHNO</intervention_name>
    <arm_group_label>Baseline</arm_group_label>
    <arm_group_label>Dopamine Release</arm_group_label>
    <arm_group_label>Endogenous Dopamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>[11C]raclopride</intervention_name>
    <arm_group_label>Baseline</arm_group_label>
    <arm_group_label>Endogenous Dopamine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. age 18 - 50 years,&#xD;
&#xD;
          2. voluntary, written, informed consent,&#xD;
&#xD;
          3. physically healthy by medical history, physical, neurological, ECG, and laboratory&#xD;
             examinations,&#xD;
&#xD;
          4. for females, non-lactating, no longer of child-bearing potential (or agree to practice&#xD;
             effective contraception during the study), and a negative serum pregnancy (B-HCG)&#xD;
             test.&#xD;
&#xD;
          5. English speaking&#xD;
&#xD;
          6. No other major Axis DSM-IV diagnosis present, besides required as below&#xD;
&#xD;
        Inclusion criteria for cocaine dependent:&#xD;
&#xD;
          1. DSM-IV criteria for Cocaine Abuse (305.60) or Cocaine Dependence (304.20)&#xD;
&#xD;
          2. recent street cocaine use,&#xD;
&#xD;
          3. intravenous and/or smoked (crack/ freebase) use,&#xD;
&#xD;
          4. positive urine toxicology screen for cocaine,&#xD;
&#xD;
        Inclusion criteria for healthy controls:&#xD;
&#xD;
          1. No current, or history of, any DSM-IV diagnosis&#xD;
&#xD;
          2. No first-degree relative with history of psychotic, mood, or anxiety disorder&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. medical contraindications to AMPT administration (e.g., known sensitivity/reaction to&#xD;
             AMPT);&#xD;
&#xD;
          2. medical contraindications to MPH administration (e.g., history of cardiac problems,&#xD;
             seizures, etc.)&#xD;
&#xD;
          3. drug or alcohol dependence (except nicotine),&#xD;
&#xD;
          4. a primary major DSM-IV psychiatric diagnosis (schizophrenia, bipolar disorder, etc.),&#xD;
             unrelated to cocaine or pathological gambling&#xD;
&#xD;
          5. positive answers on the cardiac screening questionnaire that may place the subject at&#xD;
             higher risk, as determined by cardiologist review of both the questionnaire responses&#xD;
             and screening ECG&#xD;
&#xD;
          6. current use of psychotropic and/or potentially psychoactive prescription medication,&#xD;
&#xD;
          7. physical or laboratory (B-HCG) evidence of pregnancy,&#xD;
&#xD;
          8. clotting disorders or recent anticoagulant therapy,&#xD;
&#xD;
          9. MRI-incompatible implants and other contraindications for MRI (i.e., aneurysm clip,&#xD;
             metal fragments, internal electrical devices such as a cochlear implant, spinal cord&#xD;
             stimulator or pacemaker),&#xD;
&#xD;
         10. history of claustrophobia or feeling of inability to lie still on his back for the PET&#xD;
             or MRI scans,&#xD;
&#xD;
         11. history of prior radiation exposure for research purposes within the past year such&#xD;
             that participation in this study would place them over Radioactive Drug Research&#xD;
             Committee (RDRC) limits for annual radiation exposure. This guideline is an effective&#xD;
             dose of 5 rem received per year.&#xD;
&#xD;
         12. donation or loss of 550 mL of blood or more (including plasmapheresis) or receipt of a&#xD;
             transfusion of any blood product within 8 weeks prior to the first dose of study drug.&#xD;
&#xD;
         13. use any prescription medications and/or over-the-counter medications, vitamins and/or&#xD;
             herbal supplements within 2 weeks prior to study and for the duration of the study&#xD;
             without approval from the study doctor.&#xD;
&#xD;
         14. eat grapefruit or grapefruit products, and drink alcohol, and anything containing&#xD;
             caffeine 3 days before study and during study&#xD;
&#xD;
         15. For CD subjects, &lt; 1 year of cocaine dependence, .&#xD;
&#xD;
         16. Subjects with current, past, or anticipated exposure to radiation in the workplace.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Malison, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Connecticut Mental Health Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>May 20, 2014</study_first_submitted>
  <study_first_submitted_qc>May 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2014</study_first_posted>
  <results_first_submitted>October 8, 2020</results_first_submitted>
  <results_first_submitted_qc>October 8, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 22, 2020</results_first_posted>
  <last_update_submitted>February 24, 2021</last_update_submitted>
  <last_update_submitted_qc>February 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raclopride</mesh_term>
    <mesh_term>Methylphenidate</mesh_term>
    <mesh_term>alpha-Methyltyrosine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Enrolled and Randomized</title>
          <description>This summarizes the single patient enrolled and randomized to the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Only 1 single patient was enrolled and randomized.</population>
      <group_list>
        <group group_id="B1">
          <title>Enrolled and Randomized</title>
          <description>This summarizes the single patient enrolled and randomized to the study.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                </category>
                <category>
                  <title>Male</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                </category>
                <category>
                  <title>Asian</title>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                </category>
                <category>
                  <title>Black or African American</title>
                </category>
                <category>
                  <title>White</title>
                </category>
                <category>
                  <title>More than one race</title>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <class_list>
            <class>
              <title>United States</title>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>BPND</title>
        <description>BPND is a measure of dopamine receptor availability</description>
        <time_frame>2 weeks</time_frame>
        <population>Only a single patient was enrolled and randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Enrolled and Randomized</title>
            <description>This summarizes the single patient enrolled and randomized to the study.</description>
          </group>
        </group_list>
        <measure>
          <title>BPND</title>
          <description>BPND is a measure of dopamine receptor availability</description>
          <population>Only a single patient was enrolled and randomized.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Enrolled and Randomized</title>
          <description>This summarizes the single patient enrolled and randomized to the study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gustavo Angarita, MD, Assistant Professor of Clinical Psychiatry</name_or_title>
      <organization>Yale University</organization>
      <phone>(203) 974-7536</phone>
      <email>gustavo.angarita@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

